title: Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.
abstract: OBJECTIVE
  The aim of the study was to evaluate the predictive factors of survival in patients with locally advanced squamous cell esophageal carcinoma (LASCOC) treated with definitive chemoradiotherapy (CRT) regimen based on the 5FU/CDDP combination.
  
  
  METHODS
  All patients with LASCOC treated with a definitive CRT using the 5FU/CDDP combination between 1994 and 2000 were retrospectively included. Clinical complete response (CCR) to CRT was assessed by esophageal endoscopy and CT-scan 2 mo after CRT completion. Prognostic factors of survival were assessed using univariate and multivariate analysis by the Cox regression model.
  
  
  RESULTS
  A total of 116 patients were included in the study. A CCR to CRT was observed in 86/116 (74.1%). The median survival was 20 mo (range 2-114) and the 5-year survival was 9.4%. Median survival of responder patients to CRT was 25 mo (range 3-114) as compared to 9 mo (range 2-81) in non-responder patients (P < 0.001). In univariate analysis, survival was associated with CCR (P < 0.001), WHO performance status < 2 (P = 0.01), tumour length < 6 cm (P = 0.045) and weight loss < 10% was in limit of significance (P = 0.053). In multivariate analysis, survival was dependant to CCR (P < 0.0001), weight loss < 10% (P = 0.034) and WHO performance < 2 (P = 0.046).
  
  
  CONCLUSIONS
  Our results suggest that survival in patients with LASCOC treated with definitive CRT was correlated to CCR, weight loss and WHO performance status.
authors.affiliation: Digestive Oncology Unit, Hepatogastroenterology Department, Rouen University Hospital, France. eliottdf@hotmail.com
authors.forename: Frederic
authors.initials: F
authors.lastname: Di Fiore
authors.forename: Stephane
authors.initials: S
authors.lastname: Lecleire
authors.forename: Olivier
authors.initials: O
authors.lastname: Rigal
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Galais
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Ben Soussan
authors.forename: Isabelle
authors.initials: I
authors.lastname: David
authors.forename: Bernard
authors.initials: B
authors.lastname: Paillot
authors.forename: Jacques-Henri
authors.initials: JH
authors.lastname: Jacob
authors.forename: Pierre
authors.initials: P
authors.lastname: Michel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil